<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919827</url>
  </required_header>
  <id_info>
    <org_study_id>CMM/FPI</org_study_id>
    <nct_id>NCT01919827</nct_id>
  </id_info>
  <brief_title>Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>CMM/FPI</acronym>
  <official_title>Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial Phase I, open, multicentric, non randomized, study with escalating doses, to&#xD;
      evaluate the safety and feasibility of treatment with mesenchymal stem cells in patients with&#xD;
      diagnosis of idiopathic pulmonary fibrosis.&#xD;
&#xD;
      Primary endpoint: The aim is to evaluate the safety and feasibility of the endobronchial&#xD;
      administration of mesenchymal autolog stem cells derived from bone marrow (BM-MSC)in patients&#xD;
      with mild-to-moderate idiopathic pulmonary fibrosis.&#xD;
&#xD;
      Secondary endpoint:Assess the possible effect of the infusion of BM-MSC in stopping the fall&#xD;
      of pulmonary function in patients with mild-to-moderate idiopathic pulmonary fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse side effects.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Number of participants with adverse side effects, and according to the level of severity:&#xD;
Low level: Increase in cough, fever or skin reactions&#xD;
Medium level: Infections not requiring hospital admission, mild alterations of renal or liver function&#xD;
High level: Death or major side effects requiring hospitalization:&#xD;
Worsening dyspnea with &gt;=10% reduction in forced vital capacity, reduction in arterial pressure oxygen &gt;= 10 mmHg and radiology progression between 3 months separated visits.&#xD;
Need for hospitalization due to respiratory failure requiring mechanical ventilation, worsening in gases exchange or lung infection.&#xD;
Carcinogenesis at 12 months after the endobronchial infusion of mesenchymal stem cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measures of efficacy:&#xD;
Fall in forced vital capacity as a continuous variable&#xD;
Progression of the disease defined by: Death, need for transplantation or deterioration in pulmonary function defined by fall in forced vital capacity (FVC) &gt; 10% or in lung diffusion capacity (DLCO) &gt; 15%.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>MSC endobronchial infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Endobronchial infusion of adult mesenchymal stem cells</intervention_name>
    <arm_group_label>MSC endobronchial infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mesenchymal stem cells derived from bone marrow</intervention_name>
    <arm_group_label>MSC endobronchial infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Capacity for signing informing consent and express the willing to fulfill all the&#xD;
             requirements of the study protocol during the study.&#xD;
&#xD;
          2. The patients should be, in the researcher opinion, capable to fulfill all the&#xD;
             requirements of the trial.&#xD;
&#xD;
          3. Male or female patients, 30 to 80 years old, inclusive.&#xD;
&#xD;
          4. Diagnosis of idiopathic pulmonary fibrosis according to the following criteria, based&#xD;
             on the ATS/ERS Guidelines:&#xD;
&#xD;
               1. Definite or probable usual interstitial pneumonia confirmed by surgical lung&#xD;
                  biopsy.&#xD;
&#xD;
               2. In the absence of surgical lung biopsy, all the following:&#xD;
&#xD;
             i. High resolution CT (HRCT) showing definite findings for idiopathic pulmonary&#xD;
             fibrosis (FPI): bibasal reticular opacities with minimal ground glass opacities.&#xD;
&#xD;
             ii. Absence of other known causes of FPI including toxicity from drugs, environmental&#xD;
             exposure or connective tissue diseases.&#xD;
&#xD;
             iii. Pulmonary function tests showing ventilatory restrictive pattern and/or impaired&#xD;
             gas exchange (FVC and/or DLCO &lt;90% of predicted)&#xD;
&#xD;
          5. FVC ≥ 50% of predicted value with ratio of FEV1 to FVC ≥ 0.70.&#xD;
&#xD;
          6. DLco (corrected for hemoglobin) ≥ 35% predicted value.&#xD;
&#xD;
          7. Capability of performing a 6 minutes walk test at the time of inclusion.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Any of the following:&#xD;
&#xD;
          1. Current pregnancy or lactation.&#xD;
&#xD;
          2. Findings that are diagnostic of an interstitial pneumonia or restrictive respiratory&#xD;
             disease condition other than UIP.&#xD;
&#xD;
          3. Obstructive pulmonary disease defined by FEV1/FVC &lt; 0,7 or significant emphysema on&#xD;
             HRCT.&#xD;
&#xD;
          4. Evidence of sustained improvement in FPI defined by improvement of respiratory&#xD;
             function tests before inclusion, observed in &gt;=2 test over the year prior to&#xD;
             inclusion.&#xD;
&#xD;
          5. Active or recent respiratory infection (less than 60 days before inclusion) or history&#xD;
             of frequent exacerbations of IPF from an infectious cause (more than 2/year over the&#xD;
             last 2 years)&#xD;
&#xD;
          6. Hospitalization in the 60 days prior to inclusion due to acute exacerbation of IPF.&#xD;
&#xD;
          7. Chronic cardiac failure (functional class NYHA III/IV) or left ventricular ejection&#xD;
             fraction &lt; 25%.&#xD;
&#xD;
          8. Chronically receiving corticosteroid more than 10 mg of prednisone or equivalent,&#xD;
             immunosuppressors or antifibrotic agents, including pirfenidone, D-penicillamine,&#xD;
             colchicine, ciclosporin A, TNF-alpha antagonists, imatinib, IFN-gamma, azathioprine,&#xD;
             cyclophosphamide, within the 30 days prior to inclusion.&#xD;
&#xD;
          9. The patient requires hemodialysis, peritoneal dialysis or hemofiltration.&#xD;
&#xD;
         10. History of malignancy, with the exception of skin squamous or basocellular carcinoma&#xD;
             or cervix in situ carcinoma treated successfully.&#xD;
&#xD;
         11. History of ethanol abuse within the year prior to inclusion&#xD;
&#xD;
         12. The patient is participating in a clinical trial which includes other drugs or&#xD;
             research products within the 28 days prior to baseline assessment.&#xD;
&#xD;
         13. Comorbidities limiting life expectancy to less than 12 months from the baseline&#xD;
             assessment.&#xD;
&#xD;
         14. Medical or psychiatric condition serious or active which might interfere with the&#xD;
             treatment of study, assessment or protocol fulfillment.&#xD;
&#xD;
         15. Positive test for HBsAg, HCV antibody, syphilis screening essays, or HIV antibody at&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Servicio de Neumología, Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008 Pamplona</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neumología. Hospital Universitario de Salamanaca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic pulmonary fibrosis</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

